5/17
03:48 pm
amgn
FDA Roundup: May 17, 2024 [Yahoo! Finance]
Low
Report
FDA Roundup: May 17, 2024 [Yahoo! Finance]
5/17
01:55 pm
amgn
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC [Yahoo! Finance]
Low
Report
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC [Yahoo! Finance]
5/16
08:04 pm
amgn
U.S. FDA approves Amgen drug for small cell lung cancer [Globe and Mail, The (Toronto, Canada)]
Low
Report
U.S. FDA approves Amgen drug for small cell lung cancer [Globe and Mail, The (Toronto, Canada)]
5/16
06:46 pm
amgn
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Low
Report
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
5/16
05:10 pm
amgn
FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer [The New York Times]
Low
Report
FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer [The New York Times]
5/16
03:58 pm
amgn
FDA approves Amgen's treatment for most deadly form of lung cancer [CNBC]
Neutral
Report
FDA approves Amgen's treatment for most deadly form of lung cancer [CNBC]
5/16
03:27 pm
amgn
Amgen Drug Wins US Approval for Advanced Small Cell Lung Cancer [BNN Bloomberg (Canada)]
Low
Report
Amgen Drug Wins US Approval for Advanced Small Cell Lung Cancer [BNN Bloomberg (Canada)]
5/15
06:45 pm
amgn
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
Low
Report
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
5/12
02:49 am
amgn
Bone Metastasis Treatment Market To Reach USD 38.5 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]
Low
Report
Bone Metastasis Treatment Market To Reach USD 38.5 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]
5/11
08:49 am
amgn
We Wouldn't Be Too Quick To Buy Amgen Inc. (NASDAQ:AMGN) Before It Goes Ex-Dividend [Yahoo! Finance]
Low
Report
We Wouldn't Be Too Quick To Buy Amgen Inc. (NASDAQ:AMGN) Before It Goes Ex-Dividend [Yahoo! Finance]
5/9
04:35 pm
amgn
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
Low
Report
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
5/9
04:00 pm
amgn
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Low
Report
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
5/9
08:17 am
amgn
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Mizuho from $223.00 to $235.00. They now have a "neutral" rating on the stock.
Low
Report
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Mizuho from $223.00 to $235.00. They now have a "neutral" rating on the stock.
5/8
10:51 am
amgn
Global PEGylated Proteins Market Report 2024: Revenue Data for 2021-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 [Yahoo! Finance]
Low
Report
Global PEGylated Proteins Market Report 2024: Revenue Data for 2021-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 [Yahoo! Finance]
5/7
11:13 am
amgn
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income [Yahoo! Finance]
Low
Report
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income [Yahoo! Finance]
5/6
10:48 am
amgn
Company News for May 6, 2024 [Yahoo! Finance]
Low
Report
Company News for May 6, 2024 [Yahoo! Finance]
5/6
07:41 am
amgn
Investors Pile Into Amgen in Search of Next Obesity Drug Payout [BNN Bloomberg (Canada)]
Medium
Report
Investors Pile Into Amgen in Search of Next Obesity Drug Payout [BNN Bloomberg (Canada)]
5/3
11:32 pm
amgn
Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
5/3
01:50 pm
amgn
Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending [Seeking Alpha]
Low
Report
Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending [Seeking Alpha]
5/3
01:32 pm
amgn
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $284.00 to $307.00. They now have a "neutral" rating on the stock.
Low
Report
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $284.00 to $307.00. They now have a "neutral" rating on the stock.
5/3
01:29 pm
amgn
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Morgan Stanley from $271.00 to $310.00. They now have an "equal weight" rating on the stock.
Low
Report
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Morgan Stanley from $271.00 to $310.00. They now have an "equal weight" rating on the stock.
5/3
01:29 pm
amgn
Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $332.00 to $328.00. They now have an "outperform" rating on the stock.
Low
Report
Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $332.00 to $328.00. They now have an "outperform" rating on the stock.
5/3
01:05 pm
amgn
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update [Yahoo! Finance]
Low
Report
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update [Yahoo! Finance]
5/3
12:41 pm
amgn
Apple, Amgen rise; Expedia, Fortinet fall, Friday, 5/3/2024 [Yahoo! Finance]
Low
Report
Apple, Amgen rise; Expedia, Fortinet fall, Friday, 5/3/2024 [Yahoo! Finance]
5/3
11:42 am
amgn
Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]